Barr Cuts Low-Volume Products In Post-Merger Rationalization
Executive Summary
Barr is paring low-volume products from its portfolio and pipeline following the integration of Pliva's products and R&D programs
You may also be interested in...
Barr Seeks To Capitalize On Pliva Infrastructure, Faces Obstacles To Benefits
Barr is moving ahead with its integration of Pliva, but the firm must overcome several obstacles before it can capitalize on its recently acquired European infrastructure
Barr’s Rationale For Pliva Merger: Business Synergy, Biogenerics Leadership
Barr is highlighting its complementary product portfolio and business model in its efforts to ward off competition from Actavis to acquire Pliva
NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications